Abstract:Despite advances in the treatment of acute myeloid leukemia (AML), relapse is still widely observed and represents the major cause of death among patients with AML. Treatment options in the relapse setting are limited, still relying predominantly on allogeneic hematopoietic stem cell transplantation (allo-HSCT) and cytotoxic chemotherapy, with poor outcomes. Novel targeted and venetoclax-based combinations are being investigated and have shown encouraging results. Immune checkpoint inhibitors in combination with low-intensity chemotherapy demonstrated encouraging response rates and survival among patients with relapsed and/or refractory (R/R) AML, especially in the pre- and post-allo-HSCT setting. Blocking the CD47/SIRPα pathway is another strategy that showed robust anti-leukemic activity, with a response rate of around 70% and an encouraging median overall survival in patients with newly diagnosed, higher-risk myelodysplastic syndrome and patients with AML with a TP53 mutation. One approach that was proven to be very effective in the relapsed setting of lymphoid malignancies is chimeric antigen receptor (CAR) T cells. It relies on the infusion of genetically engineered T cells capable of recognizing specific epitopes on the surface of leukemia cells. In AML, different CAR constructs with different target antigens have been evaluated and demonstrated safety and feasibility in the R/R setting. However, the difficulty of potently targeting leukemic blasts in AML while sparing normal cells represents a major limitation to their use, and strategies are being tested to overcome this obstacle. A different approach is based on endogenously redirecting the patient’s system cells to target and destroy leukemic cells via bispecific T-cell engagers (BiTEs) or dual antigen receptor targeting (DARTs). Early results have demonstrated the safety and feasibility of these agents, and research is ongoing to develop BiTEs with longer half-life, allowing for less frequent administration schedules and developing them in earlier and lower disease burden settings.

[Progress and Trend of CAR-T and PD-1 Blockade in the Treatment of Acute Myeloid Leukemia--Review].

Recent advances in CAR‐T cell therapy for acute myeloid leukaemia

Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia

Research Progress of Chimeric Antigen Receptor Modified T Cells in Treatment of Acute Myeloid Leukemia

Research Progress of Novel Drugs for Treatment of Acute Myeloid Leukemia

CAR T-cell therapy in acute myeloid leukemia

Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia

Recent Advances in Immunotherapy of Acute Leukemia Via Chimeric Antigen Receptor-Engineered T Cells

Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia

Prospect of CAR T-cell therapy in acute myeloid leukemia

CAR-T Cells in Acute Myeloid Leukemia: Where Do We Stand?

CAR-T cell therapy in AML: recent progress and future perspectives

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Advancing Chimeric Antigen Receptor T-Cell Therapy for Acute Myeloid Leukemia: Current Limitations and Emerging Strategies

Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia

A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges

An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!

A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia

CAR-T Cell Therapy Shines As a Beam of Hope in the Fight Against Acute Leukemia

Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future Progress

[Current state and future prospects of CAR T-cell therapy for myeloid malignancies]